These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19810171)

  • 1. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():163-7. PubMed ID: 19802980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
    Neu HC
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():131-4. PubMed ID: 19810175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime: comparative in-vitro study.
    Verbist L; Verhaegen J
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():67-71. PubMed ID: 19802971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H; Dette GA
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro activity of ceftazidime compared with that of other cephalosporins.
    Bint AJ; Yeoman P; Kilburn P; Anderson R; Stansfield E
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():47-51. PubMed ID: 19802968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of first, second and third generation cephalosporins.
    Forsgren A
    Acta Pathol Microbiol Scand B; 1981 Aug; 89(4):221-5. PubMed ID: 6274143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Oct; 8(4):323-31. PubMed ID: 6271726
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM; Guenthner SH; Wenzel RP
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L; Dornbusch K; Hallander HO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P; Ryan DM; Sowa MA; Watts CM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H
    Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C
    Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1983 May; 31(5):387-91. PubMed ID: 6413939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin.
    Chau PY; Ling J; Ng WS
    J Antimicrob Chemother; 1983 Oct; 12(4):337-45. PubMed ID: 6417100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.
    Baker CN; Thornsberry C; Jones RN
    Antimicrob Agents Chemother; 1980 Apr; 17(4):757-61. PubMed ID: 6249195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the in vitro activity of cefoperazone: a comparison with other beta-lactam antibiotics.
    Wise R; Gillett AP; Andrews JM
    Clin Ther; 1980; 3(Spec Issue):149-55. PubMed ID: 6446391
    [No Abstract]   [Full Text] [Related]  

  • 20. In-vitro studies with ceftazidime.
    Giamarellou H; Avlami A; Matsakas V; Kosmidis J; Daikos GK
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():73-7. PubMed ID: 19802972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.